Close Menu

NEW YORK (GenomeWeb) – A team from the Netherlands, the UK, and the US has developed a so called "drug-tolerant assay" to track tumor necrosis factor (TNF) dynamics in rheumatoid arthritis patients treated with the monoclonal antibody adalimumab, a TNF inhibitor.

Using the test, they have garnered evidence that TNF concentrations in the blood do not necessarily reflect response to the drug. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.